Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Rates improved over ...

At SGO 2026, Alison Schram, MD, highlighted first-in-class tumor suppressor reactivation and emphasized early NGS testing in ...

Next-generation sequencing (NGS) has increased the speed, scale, throughput, and accessibility of sequencing, greatly accelerating genomic research. This progress has been aided by the development of ...

The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...

SAN FRANCISCO, Nov. 13, 2025 /PRNewswire/ -- The global next-generation sequencing market size is anticipated to reach USD 42.25 billion by 2033, growing at a CAGR of 18.0% from 2025 to 2033. The next ...

The rapid evolution of HIV under antiretroviral pressure necessitates ongoing surveillance of drug resistance mutations. Next-generation sequencing (NGS) has emerged as a transformative technology in ...

Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer. Utilizing TP53 mutation status and initial disease burden at presentation to ...

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.

The US Food and Drug Administration (FDA) on Thursday issued new draft guidance meant to establish the necessary performance characteristics for genetic sequencing tests used to diagnose infectious ...

New data show precision cancer testing still lags for Black, Hispanic, low-income and Medicare/Medicaid patients, delaying ...

Clinical study on the assessment of first-line drug efficacy in advanced gastric cancer by monitoring circulating tumor cells through a self-developed microfluidic chip. Prognostic value of ...